GAS5 and bladder transitional cell carcinoma: To confirm our findings, Hedegaard et al. (n = 476) and TCGA provisional (n = 413) bladder urothelial carcinoma cohorts were used as validation cohorts for NMIBC and MIBC, respectively.28,29 The analysis of the validation cohorts confirmed the correlation of GAS5 loss with tumours of high grade, higher stage and of non-papillary histology.